HELIX SIGNS AGREEMENT WITH VIDO, A LEADING CANADIAN INFECTIOUS DISEASE
RESEARCH ORGANIZATION
(Aurora, Ontario) - Helix BioPharma Corp. through its relationship with
PharmaDerm Laboratories Inc., is pleased to announce an agreement with the
University of Saskatchewan - Veterinary Infectious Disease Organization
("VIDO") to jointly share certain vaccine technology for both human and
veterinary use.
Helix will have exclusive rights to exploit human applications of the
technology while VIDO will have exclusive rights to veterinary applications.
Revenue generated from the commercialization of this technology will be
allocated to both Helix and VIDO, according to a predetermined formula.
Helix, striving to become one of Canada's leading drug delivery companies,
is developing new injectionless vaccine delivery systems, based on its
proprietary lipid, microencapsulation process. This technology is expected
to increase patient compliance and help reduce the costs of infectious
disease.
VIDO, a leading Canadian veterinary-medical research organization with an
international reputation for animal health, is developing vaccines that will
induce a strong immunolgical response to disease causing microbes. VIDO
developed the first genetically engineered vaccine for any animal species.
Vaccine use in humans is growing throughout the world, with current annual
sales estimated by industry sources to be in excess of US$ 4 Billion.
This agreement with VIDO is the latest in Helix's series of development
partnerships, which include the University of Alberta, University of
Saskatchewan, McGill University and the Canadian Government sponsored
Protein Engineering Network of Centers of Excellence. These relationships
form an integral part of the Company's plan for accelerating the development
of its technologies by gaining access to exceptional scientists and
technical personnel and to highly sophisticated equipment that would not
otherwise be available.
The Toronto and Vancouver Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of the content of this
News Release. Information contained in this news release includes
forward-looking statements that are subject to risks and uncertainties that
could cause actual results to differ materially.
Helix BioPharma trades on the TSE and VSE under the symbol "HBP"
For further information contact:
Investor Relations
Helix BioPharma Corp.
Tel: (905) 841-2300 ext. 232
Fax: (905) 841-2244
E-mail invrelations@helixbiopharma.ca |
